Effectiveness of Antidepressants in Psychosis
Author Information
Author(s): Kjelby Eirik, Jørgensen Hugo A, Kroken Rune A, Løberg Else-Marie, Johnsen Erik
Primary Institution: Haukeland University Hospital, Norway
Hypothesis
Does differential anti-depressive effectiveness exist among second generation antipsychotics in patients acutely admitted with psychosis?
Conclusion
There was no substantial difference in anti-depressive effectiveness among olanzapine, quetiapine, risperidone, or ziprasidone in patients with psychosis.
Supporting Evidence
- A significant time-effect showing a steady decline in depressive symptoms was demonstrated.
- There were no substantial differences among the SGAs in reducing the PANSS-D score or the CDSS sum score.
- The study was funded independently of the pharmaceutical industry.
Takeaway
The study looked at different medications for depression in people with serious mental health issues and found that none worked better than the others.
Methodology
Patients were randomized to receive one of four medications and followed for up to 2 years, with assessments of depressive symptoms at multiple time points.
Potential Biases
Potential bias due to the open randomization process and the high attrition rate.
Limitations
The study's sample was heterogeneous, and the randomization process allowed for some bias in medication choice.
Participant Demographics
Adult patients acutely admitted for psychosis, with a diverse range of diagnoses.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI 0.4-4.2
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website